Warren Stone bought NEO once, on May 12, 2025

Warren Stone is the President and Chief Operating Officer (COO) of NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology diagnostics company, and serves as a corporate insider through his executive role and equity holdings in the firm.( He was appointed President & COO in April 2025 after previously serving as Chief Commercial Officer and President, Clinical Services, roles in which he led NeoGenomics’ clinical and pharma services commercial organization and helped drive salesforce optimization, commercial strategy, and digital transformation initiatives.( As President & COO, Stone oversees the company’s laboratory operations, data solutions division, and enterprise operations while maintaining responsibility for key commercial functions including clinical and pharma services, marketing, product management, and customer service.(

Stone has more than 25 years of general management and cross‑functional commercial experience in the life sciences and diagnostics sectors.( Before joining NeoGenomics in 2022, he served as President, Americas at Ortho Clinical Diagnostics (now QuidelOrtho) and previously as Senior Vice President, Life Sciences Division at MilliporeSigma, building a track record in enterprise leadership, P&L management, and business integration.( He holds an MBA from Suffolk University’s Sawyer Business School and a Bachelor of Applied Science in analytical chemistry from Technikon Witwatersrand in South Africa, along with additional certification in sales and marketing management from Damelin.( As a reporting insider, Stone has engaged in equity transactions in NeoGenomics stock, including open‑market sales and the vesting and settlement of restricted stock units as part of his compensation.(

Written by Perplexity from public sources.